Abstract: The present invention provides marine lysophosphatidylcholine compositions for use in pharmaceuticals, nutraceuticals and functional foods, as well as methods for making marine lysophosphatidylcholine compositions.

Abstract: In various embodiments methods are provided for the treatment or prophylaxis of liposomal storage diseases. In certain embodiments the methods involve administering to a subject in need thereof one or more molecular tweezers that inhibit protein aggregation.

Abstract: The present disclosure relates generally to certain compounds, pharmaceutical compositions comprising said compounds, and methods of making and using said compounds and pharmaceutical compositions. The compounds and compositions provided herein may be used for the treatment or prevention of an autoimmune disease and/or inflammatory condition, including systemic lupus erythematosus and cutaneous lupus erythematosus.

Abstract: The disclosure belongs to the technical field of organic photoelectric materials, and discloses carbonyl containing organic electroluminescent materials and use thereof in OLED. The carbonyl containing organic electroluminescent materials have a structure of formula I, wherein R1 and R2 are different in Formula I, R1 and R2 are different electron-donating groups of aromatic ring derivatives; R1 is an electron-donating groups of hole transport host materials or electron-donating groups of bipolar transport host materials. The luminescent materials of the present disclosure are organic electroluminescent materials based on derivatives of a host material and a benzoyl group. They have both AIE and delayed fluorescence characteristics with high-efficiency solid-state emission, high exciton utilization, and bipolar features.

Abstract: The invention relates to pharmaceutical compositions comprising calcium lactate as an active agent and a polysaccharide, polymer, lipid, or a combination thereof. The pharmaceutical compositions are useful treating cancer. The invention also relates to foods and nutrient compositions comprising calcium lactate.

Abstract: The present invention provides a method of using arylpiperazine derivatives for treating pulmonary fibrosis. The method comprises a step of administering to a pulmonary fibrosis patient in need thereof an effective amount of a compound of Formula 1, which is an arylpiperazine derivative.

Abstract: The present disclosure relates to a pharmaceutical combination comprising (a) a histone deacetylase inhibitor and (b) a CD38 inhibitor, FIG. 1A including combined preparations and pharmaceutical compositions thereof; uses of such combination in the treatment or prevention of cancer; and methods of treating or preventing cancer in a subject comprising administering a therapeutically effective amount of such combination.

Abstract: Disclosed herein are storage-stable ephedrine single-phase solution compositions, comprising 4 mg/mL to 6 mg/mL of ephedrine, a pH adjuster comprising acetic acid, and water, wherein the composition has a pH between 4.5 and 5.0; and wherein the pH drift of the composition is less than 0.5 after storage over at least two months at 25° C. and 60% relative humidity. Also disclosed herein are methods of making and using the same.

Abstract: The present disclosure relates to Form Z of acetic acid solvated hydrate of ponatinib hydrochloride. The present disclosure is also related to processes for the preparation of Form Z of acetic acid solvated hydrate of ponatinib hydrochloride. Further, the present disclosure also relates to pharmaceutical compositions comprising Form Z of acetic acid solvated hydrate of ponatinib hydrochloride and methods for treating disease using Form Z of acetic acid solvated hydrate of ponatinib hydrochloride.

Abstract: Stevia extracts with selected major steviol glycosides (Reb A, stevioside, Reb D, Reb C) and minor steviol glycosides and glycosylated diterpene derivative plant molecules, derived from Stevia rebaudiana plant are found to improve the perception of flavor and taste perception, which includes the sweet, savory and salty perception in a wide range of food and beverage applications.

Abstract: Provided are methods of using curcuphenol compounds to increase expression of major histocompatibility complex class I (MHC-I) antigen in cells, particularly on the surface of diseased cells such as cancer cells, and thereby increase the immunogenicity of the cells. Also provided are pharmaceutical compositions that comprise curcuphenol compounds and methods of use thereof, for instance, to treat various cancers, alone or in combination with other therapies.

Abstract: The present disclosure is directed to pharmaceutical compositions comprising sildenafil or a pharmaceutically acceptable salt thereof and one or more pharmaceutical excipients or additives wherein the pharmaceutical compositions are in the form of liquid pharmaceutical compositions. The pharmaceutical compositions of the present disclosure are useful for the treatment of diseases or conditions which are treatable by administration of sildenafil or a pharmaceutically acceptable salt thereof such as pulmonary arterial hypertension, erectile dysfunction, etc.

Abstract: A method of treatment of autism spectrum disorders comprising ergothioneine (ET), selenoneine (SeET), or combinations thereof. The methods may include the use of edible compositions comprising ergothioneine (ET), selenoneine (SeET), or combinations thereof.

Abstract: Disclosed herein is a method for alleviating a chronic liver disease, comprising administrating to a subject in need thereof a pharmaceutical composition containing rosoxacin.

Abstract: Synthesis of a compound O-{1-[(3.5-dinitrobenzoyl)amino]propan-2-yl} (4-chlorophenyl)carbamothioate and its use as an insecticidal agent.

Abstract: Embodiments methods of reducing an inflammatory immune response (e.g., inhibiting a Th1 response) and/or promoting a regulatory immune response (e.g., enhancing Treg(s)) in a mammal are provided where the method methods involve administering to the mammal a GABAA receptor positive allosteric modulator (PAM) in an amount sufficient to reduce an inflammatory immune response and/or to promote a regulatory immune response said mammal. In certain embodiments the PAM is administered in conjunction with a GABA receptor activating ligand (e.g., GABA).

Abstract: The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity. A compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof, is useful as an agent for the prophylaxis or treatment of narcolepsy.

Abstract: Methods for treating heart failure are described herein. Treatment methods include administering a cardiac sarcomere activator (e.g., omecamtiv mecarbil, or a pharmaceutically acceptable salt and/or hydrate thereof) to a subject in need thereof. Treatment methods also include adjusting a dose level of the CSA, for example, to increase, decrease, or maintain a dose level, based on the subject's plasma concentration of the CSA determined after administration of the first dose level of the CSA has started. Provided herein are also treatment methods effective to achieve a target concentration range of the CSA and dose in a single step following a single plasma concentration determination.

Abstract: The present invention relates to novel substituted azetidine dihydrothienopyridines with phosphodiesterase inhibitory activity, and to their use in therapy, and to pharmaceutical compositions comprising the compounds and to methods of treating diseases with the compounds (I)

Abstract: A new synthetic route to 4,4?-diiodoazobenzene compound using homooxidative cross-coupling of an aryl diazonium salt using a Cu-catalyzed Sandmeyer-style reaction.